CSIMarket



SciSparc Advances in Cancer, Autism, and Pain Management with Pioneering Research and Patents

Clinical Study July 22, 2024
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung CancerTel Aviv, Israel-based SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, has reported promising development in its...
Economy

Exploring the Regulatory Capabilities of MIMEDX Placental-Based Allografts in Surgical Applications

Clinical Study July 22, 2024
The use of allografts in surgical procedures has revolutionized the field of regenerative medicine. Among the leading players in this domain is MIMEDX, an innovative biopharmaceutical company specializing in placental-based allografts. In a recent pu...

AbstractIn an encouraging stride toward advancing the treatment of pulmonary sarcoidosis, aTyr P...

Clinical Study July 22, 2024
Efzofitimod in Pulmonary Sarcoidosis: Comprehensive Report on the Global Pivotal Phase 3 EFZO-FIT Study AbstractIn an encouraging stride toward advancing the treatment of pulmonary sarcoidosis, aTyr Pharma recently announced the completion of patien...

Advancing Precision Medicine Zymeworks Receives FDA Clearance for ZW191 - An Innovative Folate Receptor-Targeted Anti...

Clinical Study July 22, 2024
Zymeworks Inc., a clinical-stage biotechnology company dedicated to enhancing the standard of care for challenging diseases, has achieved a significant milestone with the clearance of its investigational new drug (IND) application for ZW191 by the Un...

Advancing Precision Medicine Zymeworks Receives FDA Clearance for ZW191 - An Innovative Folate Receptor-Targeted Anti...

Clinical Study July 22, 2024
Zymeworks Inc., a clinical-stage biotechnology company dedicated to enhancing the standard of care for challenging diseases, has achieved a significant milestone with the clearance of its investigational new drug (IND) application for ZW191 by the Un...

Mesoblast Makes Strides in Chronic Low Back Pain and Pediatric Graft Versus Host Disease Therapies Promising Developm...

Clinical Study July 22, 2024
Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, has recently made significant strides in its development of innovative treatments. The company announced the commencement of patient enrollment in a pivota...

Clinical Trial Agreements Signed 60 Degrees Pharmaceuticals Initiates Tafenoquine Babesiosis Study at Prominent Insti...

Clinical Study July 22, 2024
Abstract:60 Degrees Pharmaceuticals (60P) has recently announced the signing of clinical trial agreements with renowned research institutions, including Yale University, Tufts University, and Rhode Island Hospital. This strategic move marks the begin...

Unleashing the Potential of Inflammasome Inhibition ZyVersa Therapeutics Shines Light on Retinal Restoration and Diab...

Clinical Study July 22, 2024
Restoration of Retinal Function and Potential Treatments for Diabetes: ZyVersa Therapeutics Advances in Inflammasome InhibitionZyVersa Therapeutics, a biopharmaceutical company focused on developing innovative therapies for various disorders, has mad...

ViRobTM Pioneering Nanorobotic Platform Marks New Dawn in Cancer Treatment

Clinical Study July 22, 2024
In the dynamic field of medical technology, advancements that improve patient care and treatment outcomes are highly sought after. Microbot Medical, a pioneering medical robotic company, has recently completed the enrollment of clinical sites for its...

Pharmacokinetic Profile and Tissue Distribution of BT-600 Validated in Biora Therapeutics Phase 1 Clinical Trial

Clinical Study July 22, 2024
'Abstract:'In recent developments, Biora Therapeutics has unveiled supplemental data from its Phase 1 clinical trial of BT-600, presented at a Key Opinion Leader (KOL) event. BT-600, utilizing the innovative NaviCap platform, showcased impressive abi...
    Recently Published News

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimers Disease at the Alzheimers A...

Clinical Study July 22, 2024
Unveiling Hope: Vaccinex to Present Promising Topline Data for Pepinemab in Alzheimer's Disease at AAIC 2024The relentless quest for a breakthrough in Alzheimer's disease (AD) treatment has led researchers down myriad pathways, each holding potentia...

TheraClearX Acne Therapy System A Safe and Effective Treatment Modality for Mild to Moderate Acne

Clinical Study July 22, 2024
Acne is one of the most common skin conditions affecting millions of individuals worldwide. It not only leads to physical symptoms like redness, inflammation, and scarring but also impacts psychological well-being, self-esteem, and quality of life. A...

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy...

Clinical Study July 22, 2024
In a significant development in the field of neurodegenerative diseases, Alterity Therapeutics has reported positive interim data from their ATH434-202 Phase 2 clinical trial in Multiple System Atrophy (MSA). The company has also presented new data d...

s with the presentation of initial interim 24-week data from the Population Extension cohort of its PRISM Phase 2 cli...

Clinical Study July 22, 2024
4D Molecular Therapeutics: Trailblazing Genetic Medicines for Wet AMD and Cystic Fibrosis By Author NameEMERYVILLE, Calif. ?? In what can only be described as a groundbreaking year, 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) has announced a seri...

Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical tria...

Clinical Study July 22, 2024
'Positive Interim Results from Adverum Biotechnologies? LUNA Phase 2 Trial Presented at 2024 ASRS Annual Meeting'Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical trial for Ixo-vec (initially known...

Pioneering Prostate Cancer Treatment ORIC-944s Promising Journey Through Strategic Collaborations and Innovative Res...

Clinical Study July 22, 2024
Potential Game-Changer in Prostate Cancer Treatment: ORIC Pharmaceuticals' Innovative CollaborationsIn a significant stride towards advancing the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), ORIC Pharmaceuticals h...

Advancements in Treating Chronic Spontaneous Urticaria EMBARQ-CSU Trials Shed New Light on Barzolvolimab

Clinical Study July 22, 2024
Chronic Spontaneous Urticaria (CSU) is a debilitating and chronic skin disorder characterized by the sudden emergence of itchy hives, swelling, and other symptoms that last for six weeks or more. It affects millions of individuals worldwide, signific...

Lisata Therapeutics Completes Enrollment in Phase 2a BOLSTER Trial and Begins GBM Trial, Announces April ...

Clinical Study July 22, 2024
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, is making significant progress in its clinical trials targeting advanced solid tumors and other serious diseases. The company recently announced major developments in ...

AC Immune Strengthens Neurodegenerative Disease Treatment with Groundbreaking morADC Platform Unveiling at AAIC 2024

Clinical Study July 22, 2024
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024Neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's have long plagued humanity, caus...

FDA Greenlights Expansion of Passage Bios upliFT-D Trial for PBFT02 to Address Frontotemporal Dementia in Patients w...

Clinical Study July 22, 2024
Passage Bio Receives FDA Endorsement to Broaden upliFT-D Trial for PBFT02 to Encompass FTD-C9orf72 PatientsPassage Bio, a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disord...

Oncternal Therapeutics Advances Treatment for Metastatic Castration-Resistant Prostate Cancer with ONCT-534 Study...

Clinical Study July 22, 2024
Advancing Treatment for Metastatic Castration-Resistant Prostate Cancer: Oncternal's Progress with ONCT-534Oncternal Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently ...

Long-Term Tolerability and Efficacy of Bexotegrast at 320 mg in PSC Promising Phase 2a Trial Results...

Clinical Study July 22, 2024
'Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial Demonstrates Tolerability and Efficacy of Bexotegrast at 320 mg''Abstract'Pliant Therapeutics recently reported favorable long-term results from its INTEGRIS-PSC Phase 2a trial, showcasing tha...

INPEFA (Sotagliflozin) for Heart Failure Potential Cost-Savings and Economic Impact in Alternative Payment Models

Clinical Study July 22, 2024
Heart failure (HF) is a significant public health burden associated with high morbidity, mortality, and healthcare costs. The need for effective and cost-saving interventions is paramount, particularly in the context of alternative payment models (AP...

Assembly Biosciences Showcases Promising Preclinical Data for Novel Long-acting Helicase-Primase Inhibitors at Intern...

Clinical Study July 22, 2024
Assembly Biosciences, a leading biotechnology company focused on developing innovative treatments for viral infections, recently presented new preclinical data at the International Herpesvirus Workshop. The data showcased the potential of their inves...

Unleashing the Power of Gene Therapy BB-301 Shows Promise in OPMD TreatmentNote The title has been revised ...

Clinical Study July 22, 2024
Abstract: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising results from their Phase 1b/2...

Lexeo Therapeutics Makes Striking Progress in Gene Therapy for Cardiomyopathies, Paving the Way for Hope and Breakthr...

Clinical Study July 22, 2024
Lexeo Therapeutics Revolutionizes the Treatment of Cardiomyopathies with Promising Clinical Data and Regulatory MilestonesLexeo Therapeutics, a leading gene therapy company, made significant strides in the development of innovative treatments for car...

for the Breakthrough Data on ANX007 Shows Restored Hope for Geographic Atrophy Patients Ahead of ASRS Annu...

Clinical Study July 22, 2024
''In an exciting development in the field of ophthalmology, Annexon Biosciences announced that they will present new, compelling Phase 2 clinical data on their investigational drug ANX007 at the upcoming 42nd Annual Scientific Meeting of the American...

for the article Revolutionizing Cancer Care Indianapolis Medical Oncologists Research Advances Febrile Neutrope...

Clinical Study July 22, 2024
Indianapolis Medical Oncologist Co-authors Research Presented at International Lymphoma Symposium - A Milestone in the Management of Febrile Neutropenia in Cancer PatientsHematology Oncology of Indiana's esteemed medical oncologist, Dr. M. Sarfraz Na...

Lexeo Therapeutics to Reveal Interim Clinical Data of LX2006 for Friedreich Ataxia Cardiomyopathy in Investor Webcast...

Clinical Study July 22, 2024
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyLexeo Therapeutics, a clinical stage genetic medicine company focused on genetically defined cardi...

Unveiling the Future of Cancer Treatment CARGO Therapeutics Revolutionary Firi-cel CAR T-Cell Therapy Showcases Rema...

Clinical Study July 22, 2024
In recent groundbreaking news, renowned biotechnology firm CARGO Therapeutics has unveiled their exceptional Firi-cel CAR T-Cell Therapy in a Phase 1 Clinical Study published in The Lancet. The study has generated significant enthusiasm within the me...

Validation of OV329s Mechanism of Action and Anti-Convulsant Properties Implications for Treatment-Resistant Seizures

Clinical Study July 22, 2024
CSIMarket.com aims to provide and evidence-based information on the latest advancements in the field of pharmacology. In line with this , this article presents recent findings published in eNeuro, a peer-reviewed, open-access journal, which shed l...

Aligos Therapeutics Makes Strides in Addressing Unmet Medical Needs in Liver and Viral Diseases

Clinical Study July 22, 2024
Aligos Therapeutics, a renowned clinical-stage biopharmaceutical company, has recently made significant progress in developing innovative therapeutics to combat chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). Th...

Purple Biotech Advances Oncology Frontiers Positive Pancreatic Cancer Trial Results and New Head and Neck Cancer...

Clinical Study July 22, 2024
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company based in Rehovot, Israel, is making significant strides in oncology, with encouraging interim results from their Phase 2 pancreatic cancer study and a key dose determ...

Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95 In a move that carries...

Clinical Study July 22, 2024
'Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95''' In a move that carries promising implications for cancer therapy, Context Therapeutics has announced the acquisition of a Phase 1-ready bispecific antibody, CT-95. CT-95, a potenti...

Oxylanthanum Carbonate (OLC) A Promising Therapy for Patients with Kidney Disease

Clinical Study July 22, 2024
Unicycive Therapeutics, a clinical-stage biotechnology company, has recently released positive patient satisfaction findings from a pivotal clinical trial of Oxylanthanum Carbonate (OLC). Patients participating in the trial expressed a strong prefere...

Evolving Air Purification FDA Approves Kronos Advanced Technologies Inc.s Groundbreaking Model 8 for Healthca...

Clinical Study July 22, 2024
In recent years, the demand for advanced air purification technology has skyrocketed, driven by a growing awareness of the harmful effects of airborne contaminants on human health. Kronos Advanced Technologies Inc., a renowned leader in the field of ...

Microbot Medical Advancing Pivotal Human Clinical Trial with Promising Collaborations

Clinical Study July 22, 2024
Microbot Medical, an innovative medical technology company, is making significant progress in its pivotal human clinical trial. The recent partnership with Baptist Hospital of Miami and Brigham and Women's Hospital demonstrates the company's commitme...

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

Clinical Study July 22, 2024
AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AbstractAEON Biopharma is set to recalibrate its strategic direction toward developing biosimilars with a focused effo...

Revivas Brilaroxazine A Promising Solution Encompassing the Complexity of Pulmonary Hypertension in Divers...

Clinical Study July 22, 2024
CSIMarket.com is pleased to present a groundbreaking article that highlights the recent European patent grant covering the use of brilaroxazine for the treatment of pulmonary hypertension (PH). This patent encompasses the treatment of not only PH b...

Abiprubart A Promising Path for Addressing Sjögrens Disease Challenges

Clinical Study July 22, 2024
Sjögren's Disease is a chronic autoimmune disorder characterized by dryness of the eyes and mouth due to the immune system attacking the moisture-producing glands. It affects millions of people worldwide, predominantly women, and currently, there are...

uniQures AMT-130 Gene Therapy Shows Promise in Slowing Disease Progression in Huntingtons Disease Trials

Clinical Study July 22, 2024
Huntington's disease is a rare, inherited neurodegenerative disorder that causes the progressive deterioration of nerve cells in the brain, leading to motor, cognitive, and psychiatric symptoms. Unfortunately, there is currently no cure for this debi...

Monopar Unveils MNPR-101-Zr A Groundbreaking Radiopharmaceutical That Aims to Transform Cancer Treatment

Clinical Study July 22, 2024
WILMETTE, Ill., July 09, 2024 - Monopar Therapeutics Inc. (Nasdaq: MNPR), an innovative clinical-stage radiopharmaceutical company dedicated to advancing cancer treatments, proudly announces the enrollment of its first patient in the groundbreaking P...

Options1. Gain Therapeutics GT-02287 Passes Key Safety Milestones in Parkinsons Disease Treatment Phase 1 Stud...

Clinical Study July 22, 2024
Gain Therapeutics Achieves Key Milestones in Phase 1 Study of GT-02287, a Promising Small Molecule Therapy for Parkinson's Disease'Bethesda, Md.' - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company pioneering the discove...

Avalo Therapeutics Sets the Stage for Breakthrough HS Treatment with Active IND for AVTX-009

Clinical Study July 22, 2024
'In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009. This development allows the ...

Tafenoquine?s Potential in Combatting Persistent Babesiosis A Pioneering Clinical Trial by 60 Degrees Pharmaceutica...

Clinical Study July 22, 2024
'Tafenoquine as a Novel Therapy for Persistent Babesiosis in Immunocompromised Patients: A Pioneering Clinical Trial by 60 Degrees Pharmaceuticals'''Babesiosis, a tick-borne parasitic infection caused primarily by Babesia microti, poses a significant...

Targeted Triumph RenovoRxs Breakthrough Pancreatic Cancer Therapy Poised for Prestigious Publication ...

Clinical Study July 22, 2024
RenovoRx, an emerging pioneer in the realm of targeted cancer therapies, has recently announced a significant milestone: their latest data on the use of the RenovoCath? system and targeted therapy platform for the treatment of Locally Advanced Pancre...

Microbot Medical Initiates Pivotal Clinical Trial with First Patient Enrollment at Brigham and Womens Hospital

Clinical Study July 22, 2024
Microbot Medical, a leading medical robotics company, has achieved a significant milestone by enrolling the first patient in its pivotal human clinical trial. This groundbreaking trial, taking place at Brigham and Women's Hospital, marks a crucial st...

Merus Doses First Patient in Phase 2 Trial of Petosemtamab for mCRC and Announces Advancements in Oncology Trea...

Clinical Study July 22, 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 ?? Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies, announced the dosing of the first patien...

Unlocking Hope TANDEM Trial Explores Combining Obicetrapib and Ezetimibe to Tackle Residual Risks in High-Risk P...

Clinical Study July 22, 2024
NewAmsterdam Pharma recently announced the successful completion of patient enrollment for its pivotal Phase 3 TANDEM clinical trial. This trial aims to evaluate the efficacy and safety of a fixed-dose combination of Obicetrapib and Ezetimibe in pati...

HIL-214 Falls Short in NEST-IN1 Clinical Study, Potential Drug Development for Infants Halted

Clinical Study July 22, 2024
The NEST-IN1 Phase 2b Clinical Study conducted by HilleVax aimed to assess the efficacy of HIL-214 in infants. However, disappointing results have led the company to discontinue the drug's further development in this specific trial. This article pres...

Bio-Path Holdings Unveiling Promising Clinical Progress and Ambitious Expansion Strategies in Overcoming Oncological ...

Clinical Study July 22, 2024
CSIMarket.com presents an overview of recent updates from Bio-Path Holdings, focusing on their clinical progress and expansion plans in the treatment of various cancer indications. The article highlights the positive results from ongoing phase 2 co...

Unleashing the Power of Immuno-Oncology iTeos Forges New Pathways for Anticipated Cancer Therapies

Clinical Study July 22, 2024
iTeos Therapeutics, a clinical-stage biopharmaceutical company dedicated to revolutionizing immuno-oncology treatment options, has recently made significant progress in its pursuit of developing novel therapeutics. The company has reported the initia...
    News

Progressing Towards More Effective Breast Cancer Treatment Atossa Therapeutics EVANGELINE Trial Shows Promise in ER+...

Clinical Study July 22, 2024
Breast cancer continues to be a significant global health concern, particularly among pre-menopausal women with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa Therapeutics, a clinica...

SciSparc Advances in Cancer, Autism, and Pain Management with Pioneering Research and Patents

Clinical Study July 22, 2024
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung CancerTel Aviv, Israel-based SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company, has reported promising development in its...
Stock Market

Exploring the Regulatory Capabilities of MIMEDX Placental-Based Allografts in Surgical Applications

Clinical Study July 22, 2024
The use of allografts in surgical procedures has revolutionized the field of regenerative medicine. Among the leading players in this domain is MIMEDX, an innovative biopharmaceutical company specializing in placental-based allografts. In a recent pu...

Unleashing the Potential of Inflammasome Inhibition ZyVersa Therapeutics Shines Light on Retinal Restoration and Diab...

Clinical Study July 22, 2024
Restoration of Retinal Function and Potential Treatments for Diabetes: ZyVersa Therapeutics Advances in Inflammasome InhibitionZyVersa Therapeutics, a biopharmaceutical company focused on developing innovative therapies for various disorders, has mad...

ViRobTM Pioneering Nanorobotic Platform Marks New Dawn in Cancer Treatment

Clinical Study July 22, 2024
In the dynamic field of medical technology, advancements that improve patient care and treatment outcomes are highly sought after. Microbot Medical, a pioneering medical robotic company, has recently completed the enrollment of clinical sites for its...

Pharmacokinetic Profile and Tissue Distribution of BT-600 Validated in Biora Therapeutics Phase 1 Clinical Trial

Clinical Study July 22, 2024
'Abstract:'In recent developments, Biora Therapeutics has unveiled supplemental data from its Phase 1 clinical trial of BT-600, presented at a Key Opinion Leader (KOL) event. BT-600, utilizing the innovative NaviCap platform, showcased impressive abi...

BriaCells Immunotherapy Shows Promising Results in Metastatic Breast Cancer A Potential Game-Changer in Cancer Care

Clinical Study July 22, 2024
In recent years, immunotherapy has emerged as a groundbreaking treatment approach in the field of oncology. The ability of these therapies to harness the body's immune system to target and destroy cancer cells has offered hope to patients who had pre...

Advancing the Treatment for Adult-Onset Leukoencephalopathy Vigil Neurosciences Promising Clinical Development Strategy

Clinical Study July 22, 2024
In a recent update, Vigil Neuroscience, a pioneering biotechnology company, shared its progress in pursuing an accelerated approval pathway for their therapeutic candidate, Iluzanebart. Specifically designed for the treatment of neurodegenerative dis...

Biotechnology firm initiates Phase 3 Clinical Trial and reinforces utility of Subjective Units of Distress...

Clinical Study July 22, 2024
'Bionomics Advances Revolutionary Treatment for Social Anxiety Disorder''Biotechnology firm initiates Phase 3 Clinical Trial and reinforces utility of Subjective Units of Distress Scale as an anxiety measure in SAD'Bionomics Limited (Nasdaq: BNOX), a...

Ultragenyxs GTX-102 Angelman Syndrome Program Receives Green Light for Phase 3 Study by FDA

Clinical Study July 22, 2024
Ultragenyx Pharmaceuticals recently disclosed a successful outcome of their End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). This crucial meeting discussed the future of Ultragenyx's GTX-102 Angelman Syndrome Program, specifica...

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimers Disease at the Alzheimers A...

Clinical Study July 22, 2024
Unveiling Hope: Vaccinex to Present Promising Topline Data for Pepinemab in Alzheimer's Disease at AAIC 2024The relentless quest for a breakthrough in Alzheimer's disease (AD) treatment has led researchers down myriad pathways, each holding potentia...

TheraClearX Acne Therapy System A Safe and Effective Treatment Modality for Mild to Moderate Acne

Clinical Study July 22, 2024
Acne is one of the most common skin conditions affecting millions of individuals worldwide. It not only leads to physical symptoms like redness, inflammation, and scarring but also impacts psychological well-being, self-esteem, and quality of life. A...

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy...

Clinical Study July 22, 2024
In a significant development in the field of neurodegenerative diseases, Alterity Therapeutics has reported positive interim data from their ATH434-202 Phase 2 clinical trial in Multiple System Atrophy (MSA). The company has also presented new data d...

s with the presentation of initial interim 24-week data from the Population Extension cohort of its PRISM Phase 2 cli...

Clinical Study July 22, 2024
4D Molecular Therapeutics: Trailblazing Genetic Medicines for Wet AMD and Cystic Fibrosis By Author NameEMERYVILLE, Calif. ?? In what can only be described as a groundbreaking year, 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) has announced a seri...

Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical tria...

Clinical Study July 22, 2024
'Positive Interim Results from Adverum Biotechnologies? LUNA Phase 2 Trial Presented at 2024 ASRS Annual Meeting'Adverum Biotechnologies recently announced encouraging interim findings from its LUNA Phase 2 clinical trial for Ixo-vec (initially known...

Pioneering Prostate Cancer Treatment ORIC-944s Promising Journey Through Strategic Collaborations and Innovative Res...

Clinical Study July 22, 2024
Potential Game-Changer in Prostate Cancer Treatment: ORIC Pharmaceuticals' Innovative CollaborationsIn a significant stride towards advancing the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC), ORIC Pharmaceuticals h...

Advancements in Treating Chronic Spontaneous Urticaria EMBARQ-CSU Trials Shed New Light on Barzolvolimab

Clinical Study July 22, 2024
Chronic Spontaneous Urticaria (CSU) is a debilitating and chronic skin disorder characterized by the sudden emergence of itchy hives, swelling, and other symptoms that last for six weeks or more. It affects millions of individuals worldwide, signific...

Lisata Therapeutics Completes Enrollment in Phase 2a BOLSTER Trial and Begins GBM Trial, Announces April ...

Clinical Study July 22, 2024
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, is making significant progress in its clinical trials targeting advanced solid tumors and other serious diseases. The company recently announced major developments in ...

AC Immune Strengthens Neurodegenerative Disease Treatment with Groundbreaking morADC Platform Unveiling at AAIC 2024

Clinical Study July 22, 2024
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024Neurodegenerative diseases like Alzheimer's, Parkinson's, and Huntington's have long plagued humanity, caus...

FDA Greenlights Expansion of Passage Bios upliFT-D Trial for PBFT02 to Address Frontotemporal Dementia in Patients w...

Clinical Study July 22, 2024
Passage Bio Receives FDA Endorsement to Broaden upliFT-D Trial for PBFT02 to Encompass FTD-C9orf72 PatientsPassage Bio, a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disord...

Oncternal Therapeutics Advances Treatment for Metastatic Castration-Resistant Prostate Cancer with ONCT-534 Study...

Clinical Study July 22, 2024
Advancing Treatment for Metastatic Castration-Resistant Prostate Cancer: Oncternal's Progress with ONCT-534Oncternal Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently ...

Long-Term Tolerability and Efficacy of Bexotegrast at 320 mg in PSC Promising Phase 2a Trial Results...

Clinical Study July 22, 2024
'Positive Long-Term Data from INTEGRIS-PSC Phase 2a Trial Demonstrates Tolerability and Efficacy of Bexotegrast at 320 mg''Abstract'Pliant Therapeutics recently reported favorable long-term results from its INTEGRIS-PSC Phase 2a trial, showcasing tha...

INPEFA (Sotagliflozin) for Heart Failure Potential Cost-Savings and Economic Impact in Alternative Payment Models

Clinical Study July 22, 2024
Heart failure (HF) is a significant public health burden associated with high morbidity, mortality, and healthcare costs. The need for effective and cost-saving interventions is paramount, particularly in the context of alternative payment models (AP...

Assembly Biosciences Showcases Promising Preclinical Data for Novel Long-acting Helicase-Primase Inhibitors at Intern...

Clinical Study July 22, 2024
Assembly Biosciences, a leading biotechnology company focused on developing innovative treatments for viral infections, recently presented new preclinical data at the International Herpesvirus Workshop. The data showcased the potential of their inves...

Unleashing the Power of Gene Therapy BB-301 Shows Promise in OPMD TreatmentNote The title has been revised ...

Clinical Study July 22, 2024
Abstract: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising results from their Phase 1b/2...

Lexeo Therapeutics Makes Striking Progress in Gene Therapy for Cardiomyopathies, Paving the Way for Hope and Breakthr...

Clinical Study July 22, 2024
Lexeo Therapeutics Revolutionizes the Treatment of Cardiomyopathies with Promising Clinical Data and Regulatory MilestonesLexeo Therapeutics, a leading gene therapy company, made significant strides in the development of innovative treatments for car...

for the Breakthrough Data on ANX007 Shows Restored Hope for Geographic Atrophy Patients Ahead of ASRS Annu...

Clinical Study July 22, 2024
''In an exciting development in the field of ophthalmology, Annexon Biosciences announced that they will present new, compelling Phase 2 clinical data on their investigational drug ANX007 at the upcoming 42nd Annual Scientific Meeting of the American...

for the article Revolutionizing Cancer Care Indianapolis Medical Oncologists Research Advances Febrile Neutrope...

Clinical Study July 22, 2024
Indianapolis Medical Oncologist Co-authors Research Presented at International Lymphoma Symposium - A Milestone in the Management of Febrile Neutropenia in Cancer PatientsHematology Oncology of Indiana's esteemed medical oncologist, Dr. M. Sarfraz Na...

Lexeo Therapeutics to Reveal Interim Clinical Data of LX2006 for Friedreich Ataxia Cardiomyopathy in Investor Webcast...

Clinical Study July 22, 2024
Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia CardiomyopathyLexeo Therapeutics, a clinical stage genetic medicine company focused on genetically defined cardi...

Unveiling the Future of Cancer Treatment CARGO Therapeutics Revolutionary Firi-cel CAR T-Cell Therapy Showcases Rema...

Clinical Study July 22, 2024
In recent groundbreaking news, renowned biotechnology firm CARGO Therapeutics has unveiled their exceptional Firi-cel CAR T-Cell Therapy in a Phase 1 Clinical Study published in The Lancet. The study has generated significant enthusiasm within the me...

Validation of OV329s Mechanism of Action and Anti-Convulsant Properties Implications for Treatment-Resistant Seizures

Clinical Study July 22, 2024
CSIMarket.com aims to provide and evidence-based information on the latest advancements in the field of pharmacology. In line with this , this article presents recent findings published in eNeuro, a peer-reviewed, open-access journal, which shed l...

Aligos Therapeutics Makes Strides in Addressing Unmet Medical Needs in Liver and Viral Diseases

Clinical Study July 22, 2024
Aligos Therapeutics, a renowned clinical-stage biopharmaceutical company, has recently made significant progress in developing innovative therapeutics to combat chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). Th...

Purple Biotech Advances Oncology Frontiers Positive Pancreatic Cancer Trial Results and New Head and Neck Cancer...

Clinical Study July 22, 2024
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage biopharmaceutical company based in Rehovot, Israel, is making significant strides in oncology, with encouraging interim results from their Phase 2 pancreatic cancer study and a key dose determ...

Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95 In a move that carries...

Clinical Study July 22, 2024
'Context Therapeutics Acquires Phase 1-ready T Cell Engager CT-95''' In a move that carries promising implications for cancer therapy, Context Therapeutics has announced the acquisition of a Phase 1-ready bispecific antibody, CT-95. CT-95, a potenti...

Oxylanthanum Carbonate (OLC) A Promising Therapy for Patients with Kidney Disease

Clinical Study July 22, 2024
Unicycive Therapeutics, a clinical-stage biotechnology company, has recently released positive patient satisfaction findings from a pivotal clinical trial of Oxylanthanum Carbonate (OLC). Patients participating in the trial expressed a strong prefere...

Evolving Air Purification FDA Approves Kronos Advanced Technologies Inc.s Groundbreaking Model 8 for Healthca...

Clinical Study July 22, 2024
In recent years, the demand for advanced air purification technology has skyrocketed, driven by a growing awareness of the harmful effects of airborne contaminants on human health. Kronos Advanced Technologies Inc., a renowned leader in the field of ...

Microbot Medical Advancing Pivotal Human Clinical Trial with Promising Collaborations

Clinical Study July 22, 2024
Microbot Medical, an innovative medical technology company, is making significant progress in its pivotal human clinical trial. The recent partnership with Baptist Hospital of Miami and Brigham and Women's Hospital demonstrates the company's commitme...

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

Clinical Study July 22, 2024
AEON Biopharma Shifts Strategic Focus: Pioneers Biosimilar Pathway for ABP-450 with Proactive Phase 3 Trials and Promising Results AbstractAEON Biopharma is set to recalibrate its strategic direction toward developing biosimilars with a focused effo...

Revivas Brilaroxazine A Promising Solution Encompassing the Complexity of Pulmonary Hypertension in Divers...

Clinical Study July 22, 2024
CSIMarket.com is pleased to present a groundbreaking article that highlights the recent European patent grant covering the use of brilaroxazine for the treatment of pulmonary hypertension (PH). This patent encompasses the treatment of not only PH b...

Abiprubart A Promising Path for Addressing Sjögrens Disease Challenges

Clinical Study July 22, 2024
Sjögren's Disease is a chronic autoimmune disorder characterized by dryness of the eyes and mouth due to the immune system attacking the moisture-producing glands. It affects millions of people worldwide, predominantly women, and currently, there are...

uniQures AMT-130 Gene Therapy Shows Promise in Slowing Disease Progression in Huntingtons Disease Trials

Clinical Study July 22, 2024
Huntington's disease is a rare, inherited neurodegenerative disorder that causes the progressive deterioration of nerve cells in the brain, leading to motor, cognitive, and psychiatric symptoms. Unfortunately, there is currently no cure for this debi...

Monopar Unveils MNPR-101-Zr A Groundbreaking Radiopharmaceutical That Aims to Transform Cancer Treatment

Clinical Study July 22, 2024
WILMETTE, Ill., July 09, 2024 - Monopar Therapeutics Inc. (Nasdaq: MNPR), an innovative clinical-stage radiopharmaceutical company dedicated to advancing cancer treatments, proudly announces the enrollment of its first patient in the groundbreaking P...

Options1. Gain Therapeutics GT-02287 Passes Key Safety Milestones in Parkinsons Disease Treatment Phase 1 Stud...

Clinical Study July 22, 2024
Gain Therapeutics Achieves Key Milestones in Phase 1 Study of GT-02287, a Promising Small Molecule Therapy for Parkinson's Disease'Bethesda, Md.' - Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company pioneering the discove...

Avalo Therapeutics Sets the Stage for Breakthrough HS Treatment with Active IND for AVTX-009

Clinical Study July 22, 2024
'In a remarkable stride towards innovative treatment options for Hidradenitis Suppurativa (HS), Avalo Therapeutics, Inc. recently announced the active status of its Investigational New Drug (IND) application for AVTX-009. This development allows the ...

Tafenoquine?s Potential in Combatting Persistent Babesiosis A Pioneering Clinical Trial by 60 Degrees Pharmaceutica...

Clinical Study July 22, 2024
'Tafenoquine as a Novel Therapy for Persistent Babesiosis in Immunocompromised Patients: A Pioneering Clinical Trial by 60 Degrees Pharmaceuticals'''Babesiosis, a tick-borne parasitic infection caused primarily by Babesia microti, poses a significant...

Targeted Triumph RenovoRxs Breakthrough Pancreatic Cancer Therapy Poised for Prestigious Publication ...

Clinical Study July 22, 2024
RenovoRx, an emerging pioneer in the realm of targeted cancer therapies, has recently announced a significant milestone: their latest data on the use of the RenovoCath? system and targeted therapy platform for the treatment of Locally Advanced Pancre...

Microbot Medical Initiates Pivotal Clinical Trial with First Patient Enrollment at Brigham and Womens Hospital

Clinical Study July 22, 2024
Microbot Medical, a leading medical robotics company, has achieved a significant milestone by enrolling the first patient in its pivotal human clinical trial. This groundbreaking trial, taking place at Brigham and Women's Hospital, marks a crucial st...

Merus Doses First Patient in Phase 2 Trial of Petosemtamab for mCRC and Announces Advancements in Oncology Trea...

Clinical Study July 22, 2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 ?? Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company specializing in the development of innovative, full-length multispecific antibodies, announced the dosing of the first patien...

Unlocking Hope TANDEM Trial Explores Combining Obicetrapib and Ezetimibe to Tackle Residual Risks in High-Risk P...

Clinical Study July 22, 2024
NewAmsterdam Pharma recently announced the successful completion of patient enrollment for its pivotal Phase 3 TANDEM clinical trial. This trial aims to evaluate the efficacy and safety of a fixed-dose combination of Obicetrapib and Ezetimibe in pati...

HIL-214 Falls Short in NEST-IN1 Clinical Study, Potential Drug Development for Infants Halted

Clinical Study July 22, 2024
The NEST-IN1 Phase 2b Clinical Study conducted by HilleVax aimed to assess the efficacy of HIL-214 in infants. However, disappointing results have led the company to discontinue the drug's further development in this specific trial. This article pres...

Bio-Path Holdings Unveiling Promising Clinical Progress and Ambitious Expansion Strategies in Overcoming Oncological ...

Clinical Study July 22, 2024
CSIMarket.com presents an overview of recent updates from Bio-Path Holdings, focusing on their clinical progress and expansion plans in the treatment of various cancer indications. The article highlights the positive results from ongoing phase 2 co...

Unleashing the Power of Immuno-Oncology iTeos Forges New Pathways for Anticipated Cancer Therapies

Clinical Study July 22, 2024
iTeos Therapeutics, a clinical-stage biopharmaceutical company dedicated to revolutionizing immuno-oncology treatment options, has recently made significant progress in its pursuit of developing novel therapeutics. The company has reported the initia...

Pioneering the Future Microbot Medicals Revolutionary Clinical Trial Gains Momentum at Baptist Hospital of Miami

Clinical Study July 22, 2024
'Abstract:'Microbot Medical, a frontrunner in the field of medical technology, has expanded its pivotal human clinical trial to Baptist Hospital of Miami following FDA approval. This expansion marks a critical step in the company's mission to innovat...

Spectral AI Expands Clinical Trial Sites for Pivotal U.S. Burn Study

Clinical Study July 22, 2024
Advancements in AI-Driven Burn Diagnostics: Spectral AI's Pivotal U.S. Burn Study Expands, Nearing Critical Enrollment Milestones By , M.D. Published in CSIMarket.com DALLAS, July 2024 ?? Spectral AI, Inc. (Nasdaq: MDAI), an innovator in artificial...

Apollomics Announces Strategic Focus on Vebreltinib Study Enrollment for NSCLC Patients with Met Amplification Mutations

Clinical Study July 22, 2024
Apollomics, a biopharmaceutical company, recently unveiled its updated strategic focus, emphasizing the enrollment of non-small cell lung cancer (NSCLC) patients with Met Amplification mutations in the vebreltinib study. This new direction aims to ad...

AbstractRecent advancements in targeted therapies have solidified their role in the treatment of...

Clinical Study July 22, 2024
Breaking New Grounds in Therapy: Dupilumab's Unprecedented Approval for COPD and Linvoseltamab's Promising Results in Multiple Myeloma AbstractRecent advancements in targeted therapies have solidified their role in the treatment of complex, multi-fa...

Gyre Therapeutics Announces Chinas NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ...

Clinical Study July 22, 2024
Gyre Therapeutics Gains NMPA Approval, Marking a Milestone for Treating CLD-Associated Thrombocytopenia in ChinaGyre Therapeutics Announces China's NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated ThrombocytopeniaGyr...

Alvotech Delivers Promising Topline Results for Biosimilar AVT03, Targeting Prolia and Xgeva Markets

Clinical Study July 22, 2024
Alvotech, a global player in the biotech space, has recently announced positive topline results from a pivotal confirmatory study for its biosimilar candidate, AVT03. This product is designed as a proposed biosimilar to two widely used denosumab-base...

Telomir Pharmaceuticals Joins Russell 3000 and Microcap Indexes, Strengthening Position in Pharmaceutical Market

Clinical Study July 22, 2024
'TAMPA, Fla., July 02, 2024' - Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company specializing in the development and commercialization of Telomir-1, a revolutionary small molecule aimed at lengthening the prote...



Previous News 1. Page 2. Page 3. Page 4. Page .... 51. Page .... 101. Page NEXT 


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com